New! Sign up for our free email newsletter.
Science News
from research organizations

PAD4 inhibition in neutrophils halts cancer progression and metastasis

Novel PAD4 inhibitor reduces primary tumor, metastases and enhances checkpoint inhibitor treatments

Date:
September 7, 2022
Source:
The Wistar Institute
Summary:
Researchers have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression.
Share:
FULL STORY

Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therapeutics Inc. have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression. The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments. Jubilant Therapeutics Inc. is developing a novel small molecule PAD4 inhibitor that directly targets this mechanism. The findings appear in Cancer Research, a journal of the American Association for Cancer Research.

"Development of metastases remains a leading cause of death from cancer. Tumor-associated neutrophils have long been implicated in cancer progression. Understanding the mechanisms by which these cells promote tumor growth and metastatic spread is critically important for the development of new treatments," shares Yulia Nefedova, M.D., Ph.D., associate professor, Immunology, Microenvironment & Metastasis Program, Ellen and Ronald Caplan Cancer Center of The Wistar Institute.

This research revealed the importance of PAD4 protein in the migration of neutrophils, specialized white blood cells that serve as the first line of immune defense in the body, directly impacting both primary tumor growth and secondary malignant tumor spread. Both genetic deletion of PAD4 and pharmacological inhibition of PAD4 using Jubilant Therapeutic Inc's novel inhibitor dramatically down-regulated chemokine CXCR2, reduced immune suppressive polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) at tumor and metastatic sites, activated T cells, and synergized with immune checkpoint blockade.

All results point to a potent anti-tumor effect of PAD4 inhibition to target PMN-MDSCs in the tumor microenvironment. This finding is being further investigated in Wistar's Nefedova laboratory.

"These results highlight the potential of PAD4 inhibition as a novel treatment approach for cancer in addition to the previously established role of this pathway in autoimmune diseases," said Luca Rastelli, Ph.D., Chief Scientific Officer, Jubilant Therapeutics Inc. "We are developing several highly selective oral, small molecule PAD4 inhibitors, with the goal of bringing this novel mechanism to the clinic as potential therapeutics for tumor metastasis in colorectal and pancreatic cancers, patients with liver metastasis as well as for both acute and chronic autoimmune/inflammatory diseases."

These findings were only made possible through the supportive collaboration between Wistar, a Philadelphia based nonprofit biomedical research institute, and Jubilant Therapeutics Inc., a clinical-stage precision therapy company developing new therapies to treat oncology and autoimmune disease.

"Only working together are we able to efficiently translate our fundamental research discoveries into clinical realities," states Heather Steinman, Ph.D., MBA, The Wistar Institute vice president for Business Development & executive director of Technology Transfer.

Co-authors: Hui Deng, Cindy Lin, Laura Garcia-Gerique, Shuyu Fu, Zachary Cruz, Erin Bonner Matthew Rosenwasser, Sridharan Rajagopal, M. Naveen Sadhu, Chandru Gajendran, Mohd Zainuddin, Ramachandraiah Gosu, Dhanalakshmi Sivanandhan, Miriam A. Shelef, Brian Nam, Dan T. Vogl, and Dmitry I. Gabrilovich.


Story Source:

Materials provided by The Wistar Institute. Note: Content may be edited for style and length.


Journal Reference:

  1. Hui Deng, Cindy Lin, Laura Garcia-Gerique, Shuyu Fu, Zachary Cruz, Erin E. Bonner, Matthew Rosenwasser, Sridharan Rajagopal, M Naveen Sadhu, Chandru Gajendran, Mohd Zainuddin, Ramachandraiah Gosu, Dhanalakshmi Sivanandhan, Miriam A. Shelef, Brian Nam, Dan T. Vogl, Dmitry I. Gabrilovich, Yulia Nefedova. A novel selective inhibitor JBI-589 targets PAD4-mediated neutrophil migration to suppress tumor progression. Cancer Research, 2022; DOI: 10.1158/0008-5472.CAN-21-4045

Cite This Page:

The Wistar Institute. "PAD4 inhibition in neutrophils halts cancer progression and metastasis." ScienceDaily. ScienceDaily, 7 September 2022. <www.sciencedaily.com/releases/2022/09/220907105511.htm>.
The Wistar Institute. (2022, September 7). PAD4 inhibition in neutrophils halts cancer progression and metastasis. ScienceDaily. Retrieved July 24, 2024 from www.sciencedaily.com/releases/2022/09/220907105511.htm
The Wistar Institute. "PAD4 inhibition in neutrophils halts cancer progression and metastasis." ScienceDaily. www.sciencedaily.com/releases/2022/09/220907105511.htm (accessed July 24, 2024).

Explore More

from ScienceDaily

RELATED STORIES